Board of directors
Management team
Company overview

Company overview 

QuiaPEG Pharmaceuticals AB is an emerging biotech company developing biopharmaceuticals based on a proprietary, cutting-edge PEGylation technology platform. The company´s technology is applicable on proteins, peptides and small molecules and offers a unique half-life extension platform. The technology offers improved patient convenience, new patent lives and a substantial reduction in cost-of-goods.

The company is initially developing novel long-acting biopharmaceuticals for the treatment of metabolic disorders using the company´s proprietary technology platform. The company´s lead project is intended to reduce the burden of frequent injection therapy by requiring significantly fewer injections, potentially improving compliance and yielding better treatment outcomes.

The company was founded in 2012 and is headquartered at Karolinska Institutet Science Park, Stockholm, Sweden.


Our mission 

QuiaPEG Pharmaceuticals develops improved versions of clinically validated drugs by using its proprietary PEGylation technology. The mission is to create new proprietary drugs enhancing patient convenience and compliance.

QuiaPEG Pharmaceuticals Holding AB

Virdings Allé 32 B
754 54 Uppsala
+46 (0) 70 693 12 53

User terms & privacy policy
Send a message